MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
Recruiting
Observational Study
Kidney Transplant; Complications
Liver Transplant; Complications
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- University of Rome Tor Vergata · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Kidney transplant recipient at our Institution
* Liver transplant recipient at our Institution
Exclusion Criteria:
* Re-transplantation
* Dual kidney transplantation
* Combined transplant (kidney-liver, kidney-pancreas)
* Autoimmune disease as indication to transplant
Contacts